GlassScriptPhysician profile
Margaret K Poulos
NPI 1477546851
$7,634.81
in general payments reported to CMS, 2019-2025
25 companies · $1,084 in 2025
The $1,084 reported for 2025 was more than what 79% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,443 · 2020: $535 · 2021: $1,388 · 2022: $1,139 · 2023: $967 · 2024: $1,079 · 2025: $1,084.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,129.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $1,349.47 | 2019-2022 | |
| Abbvie INC. | $1,338.76 | 2022-2025 | |
| Alcon Vision LLC | $1,010.26 | 2019-2025 | Clareon, Rocklatan, Tryptyr |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $785.36 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $559.17 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $404.53 | 2019-2025 | Cequa |
| Aerie Pharmaceuticals, INC. | $325.57 | 2021 | |
| Harrow Eye, LLC | $288.08 | 2024-2025 | Vevye |
| Bausch & Lomb Americas INC. | $286.42 | 2022-2024 | Prolensa, Vyzulta, Alrex |
| Amgen INC. | $271.96 | 2024 | Tepezza |
| Rayner Intraocular Lenses Limited | $198.80 | 2023-2025 | Rayone Spheric, Rayone Emv, Rayone Aspheric |
| Novartis Pharmaceuticals Corporation | $184.96 | 2019-2023 | |
| Ocular Therapeutix, INC. | $117.12 | 2023 | Dextenza |
| Mallinckrodt Hospital Products INC. | $98.77 | 2023-2025 | Acthar |
| Horizon Therapeutics Plc | $84.98 | 2021-2023 | Tepezza |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $56.80 | 2020-2024 | |
| Oyster Point Pharma, INC. | $47.92 | 2023-2025 | Tyrvaya, Ryzumvi |
| Sight Sciences, INC. | $38.15 | 2022 | |
| Eyevance Pharmaceuticals LLC | $33.53 | 2019-2021 | |
| Thea Pharma INC. | $33.48 | 2024 | Iyuzeh |
| Tarsus Pharmaceuticals, INC. | $32.93 | 2025 | Xdemvy |
| Dompe US, INC. | $29.09 | 2019 | |
| Glaukos Corporation | $21.28 | 2024 | Idose |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Johnson & Johnson Surgical Vision, INC. | $18.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margaret Poulos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.